An observational study in Breast Cancer, Breast Neoplasm and Artificial Intelligence, sponsored by Seoul National University Hospital. Completed at 1 site in South Korea. Open to female participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-06.
Sponsored by Seoul National University Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 50 studies in Breast Neoplasms by Seoul National University Hospital — 13 open to participants now, 21 under way, 3 of them phase 3. Breast Neoplasms · Seoul National University Hospital.
Among the 50 studies in Breast Neoplasms by Seoul National University Hospital, this one is the 15th largest by enrollment of the 22 observational ones that give a count, is one of 8 that started in 2022, is one of 22 observational ones, and was the 45th registered.
14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.
Browse Breast Neoplasms studies →13 of the 50 studies in Breast Neoplasms by Seoul National University Hospital are open now, in 1 country. Recruiting first, the newest first:
Seoul National University Hospital · Sites in Korea, Republic of
Ages 19+ · Women only
Seoul National University Hospital · Sites in Korea, Republic of
Ages 19+
Seoul National University Hospital · Sites in Korea, Republic of
Ages 19+
Seoul National University Hospital · Sites in Korea, Republic of
Ages 40–69 · Women only
Seoul National University Hospital · Sites in Korea, Republic of
Ages 20+ · Women only
By country, each count listing its studies:
Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 18 Years to 80 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
50 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 12 · Phase 3 5 · Phase 4 1
First in 2006; this study’s year is marked. 8 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 200 is close to the median of 184 across 3,239 observational studies indexed under Breast Neoplasms.
Median enrollment 114 across the 28 interventional studies, 352 across the 22 observational. Of the 21 that completed or were terminated, 3 (14%) have results posted.
This tab as a report to print or save as PDF → With an account.
Seoul National University Hospital is the lead sponsor of 1,903 studies on the registry; 276 are open to participants now.
Of its 12 completed or terminated interventional studies of FDA-regulated products, 2 (17%) have results posted.
3 of the studies in Breast Neoplasms by Seoul National University Hospital that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05440149Phase 3Seoul National University HospitalThe Postoperative Radiotherapy in N1 Breast Cancer Patients | 2026-12-31 |
| NCT03594396Seoul National University HospitalWindow of Opportunity Trial of Neoadjuvant Olaparib and Durvalumab for Triple Negative or Low ER+ Breast Cancer | 2026-12-31 |
| NCT04892693Seoul National University HospitalTalazoparib in Advanced Breast Cancer Patients With Homologous Recombinant Deficiency | 2027-05-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 50 studies in Breast Neoplasms by Seoul National University Hospital, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The accuracy of breast examinations and ultrasonography performed clinically to detect breast mass varies greatly depending on the physician\'s skill level, and the accuracy of breast examinations by non-experts is particularly low. In this study, we aimed to validate whether the concurrent use of ultrasound sensor technology is an efficient strategy for the purpose of improving the sensitivity of detecting breast masses through breast examination.
[Background] This research team would like to conduct this study based on the idea that the sensitivity of breast palpation can be improved by moving away from traditional breast palpation, which is simply performed by hand, and using auxiliary examination equipment based on ultrasonic sensor technology. In particular, our research team focused on the waveform of the ultrasound itself rather than the visual images obtained through the ultrasound device. In the existing breast ultrasound, the medical staff reads images created through ultrasound from multiple sensors to confirm the possibility of breast cancer, and this is read based on the medical staff\'s very subjective opinions. However, ultrasonic waveforms acquired through ultrasound can store information about the waveform as data and thus be implemented as objective values.
[Study design] Prospective, multi-institutional
[Study protocol]
① Preoperative ultrasound sensor-based diagnostic equipment was applied to 200 patients with breast mass among patients admitted to the breast surgery department, and prospectively obtained ultrasound echo signal data generated by the mass.
② For this purpose, the researcher uses equipment containing a single ultrasound sensor to manually scan the mass lesion area and no evidence disease area.
③ Diagnostic performance (judgment for presence or absence of a tumor) of diagnostic tool based on ultrasound sensor technology through an artificial intelligence algorithm designed based on ultrasound wavelength and frequency optimized for mass detection.
[Objectives]
scheduled for surgery after a tumor has been confirmed on breast ultrasound examination
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Device performance
Sensitivity/specificity/predictive value/accuracy/positive predictive value/ negative predictive value of diagnostic performance
Time frame: Within 1 year after the study participant registration deadline
Artificial intelligence algorithm efficacy
Time frame: Within 2 year after the study participant registration deadline
Plan to share: No
No publications or documents are linked to this record.
Ran from Oct 2022 to primary completion in Jan 2024, 15 months.
Of 1,193 non-industry observational studies under Breast Neoplasms, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 139. This study's 15 months is below that.
Counting every sponsor, half of 1,382 studies reached it within 55 months; a quarter within 25 and three quarters within 126.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 6, 2026: start Oct 2024 → Oct 2022, primary completion Feb 2025 → Jan 2024 and completion Apr 2025 → Jan 2025.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Seoul National University Hospital →